Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXDocumented mass on examination or imaging at site of DCIS prior to biopsy yielding diagnosis of DCIS, with exception of fibroadenoma at a distinct/separate site from site of DCIS. In cases of uncertainty about whether the mass was present on physical examination prior to biopsy, the following criteria should be applied: if mammogram noting abnormal findings is diagnostic MMG = symptomatic/if mammogram noting abnormal findings is screening MMG = asymptomaticXx_NEWLINE_xXMammographic finding of BIRADS 4 or greater within 6 months of registration at site other than that of known DCIS, without pathologic assessmentXx_NEWLINE_xXPatients that are determined to have a rare cancer with unknown primary site are eligible under cohort #32 (tumor of unknown primary [cancer of unknown primary; CuP]), provided that there is histologic documentation of metastatic malignancy with no discernible primary site identified from histopathologic review, physical exam and associated cross-sectional imaging of the chest, abdomen, and pelvisXx_NEWLINE_xXNOTE: Patient must meet all eligibility criteria outlined in pre-registration; patient may not be randomized until site has been notified that the central determination of p53 mutation status of the surgical tumor tissue has been completed and site has been notified of assay completionXx_NEWLINE_xXPatients must have a minimum of five, available unstained slides from the residual (post-neoadjuvant) invasive tumor in primary site or lymph node; (these will be submitted to determine PD-L1 expression) the tumor tissue must be adequate for PD-L1 testing, which typically requires a minimum of 100 cancer cells per slide\r\n* NOTE: Initial order for specimen kits should be placed at least two weeks prior to registering the first patient at each siteXx_NEWLINE_xXSite must verify that there is no known change in the step 1 eligibility since initial registrationXx_NEWLINE_xXSubmission of tumor tissue is required for all patients; investigators should check with their site pathology department regarding release of biospecimens before approaching patients about participation in the trialXx_NEWLINE_xXMRD results will be reported to the submitting institution\r\n* NOTE: FOR MRD ASSESSMENTS, AN ASPIRATE FROM A SEPARATE BONE MARROW ASPIRATION SITE MUST BE SUBMITTED (THE NEEDLE CAN BE RE-DIRECTED THROUGH THE SAME SKIN PUNCTURE SITE); ONLY SUBMIT ASPIRATES FROM THE FIRST PULL OF AN ASPIRATION SITE FOR MRD TESTING; DO NOT SUBMIT SAMPLES FROM THE SECOND OR THIRD PULL OF THE SAME ASPIRATION SITE \r\n* In B-lineage ALL, MRD levels in peripheral blood or from a dilute marrow aspiration can be 300% lower, on average, than those in bone marrow at a given time point; submitting a first pull from a separate aspiration site will ensure that MRD determinations used in randomization and trial interpretation are accurate\r\n** NOTE: failure to submit bone marrow aspirates will result in a major violation at the time of an auditXx_NEWLINE_xXPatients with regional node involvement as their only site of disease beyond the primary tumor will not be eligibleXx_NEWLINE_xXTissue must have been determined to have local 1p/9q co-deletion and IDH mutation prior to submission for central path review\r\n* Tumor tissue must show co-deletion of chromosomes 1p and 19q; for eligibility, the 1p/19q analysis results will be accepted from the local site, as determined by either a locally available or reference laboratory (for US, must be Clinical Laboratory Improvement Act [CLIA] certified); acceptable methods for determination of 1p/19q loss include fluorescent in-situ hybridization (FISH), by genomic sequencing or methylomic analyses; US and Canadian sites must send a copy of the official report to the pathology coordinator and quality assurance specialist (QAS)\r\n* Tumor must also show evidence of IDH mutation by immunohistochemistry or genomic analyses; this should be performed at the local site (US: performed in a CLIA certified laboratory); the site must send a copy of the official report to the pathology coordinator and QASXx_NEWLINE_xXNo more than 3 prior regimens for large cell component (e.g. one induction and two salvage therapies); monoclonal antibody alone or involved field/involved site radiotherapy do not count as lines of therapyXx_NEWLINE_xXAs of Amendment 2, if the registering site is a photon center (registering patients to group I), the patient must agree to participate in the advanced imaging sub-studyXx_NEWLINE_xXAny site of distant disease (for example, drop metastases from the GBM tumor site)Xx_NEWLINE_xXCarcinoma of unknown primary site.Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXSubjects who have received any radiotherapy to the primary sample site within the last 14 days (radiation may be included in treatment decision after biopsy).Xx_NEWLINE_xXthe safety or well-being of the participant or study staffXx_NEWLINE_xXPatients planning to enroll in this study must first have a slot reserved in advance of the registration; all site staff will use OPEN to create a slot reservationXx_NEWLINE_xXPrimary tumor site: oral cavity, oropharynx, larynx, hypopharynxXx_NEWLINE_xXPathology slides from tumor tissue obtained by surgical excision or core biopsy must be reviewed by the designated site pathologist, or backup pathologist, prior to study entry; confirmation of the diagnosis must be documented by the AMC-approved pathologist prior to study entry; please reference the AMC-068 Manual of Procedures (MOP) for further instructions on documenting the diagnosis; the site pathologist for non-Hodgkin lymphoma (NHL) must be approved through the AMC's external quality assurance (EQA) processXx_NEWLINE_xXParticipants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issueXx_NEWLINE_xXThere is at least 1 metastatic site at one or more of the following sites: spine or non-spine bone and at maximum 5 sites can be treated on protocolXx_NEWLINE_xXSurgically unresectable site as determined by tumor board or surgeon or patients who decline surgeryXx_NEWLINE_xXAt least 1 site of disease must be accessible to provide repeat biopsies for tumor tissue for sequence and immunological analysis. This site may be a target lesion as long as it will not be made unmeasurable by the biopsy procedure.Xx_NEWLINE_xXHas histologically-confirmed cSCC as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).Xx_NEWLINE_xXPresence of at least one measurable lesion as defined by RECIST version (v)1.1; a previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the completion of irradiationXx_NEWLINE_xXPatients must agree to have a biopsy of metastatic tissue at baseline, and there must be a lesion that can be biopsied with acceptable clinical risk (as judged by the investigator)\r\n* Patients with unsuccessful baseline biopsies may undergo an additional biopsy attempt (at the same or a different site, determined by the investigator)\r\n* For patients with an intact primary and no metastatic site that can be safely biopsied, biopsy of the primary is acceptable, but must be approved by the principal investigator\r\n* Baseline tumor biopsy may be omitted if the tumor is inaccessible and/or a biopsy is not thought to post exceptionally high procedural risk due to location or other factorsXx_NEWLINE_xXAt least 2 weeks since last radiotherapy. If radiation was localized to the only site of measurable disease, there must be documentation of disease progression of the irradiated site. Subjects must have recovered from all acute toxicities from radiotherapy.Xx_NEWLINE_xXIs or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subjectXx_NEWLINE_xXOligometastatic state is defined by =< 3 active sites of disease, including the primary siteXx_NEWLINE_xXCarcinoid tumors of any site are eligible; patients with pancreatic neuroendocrine tumors are excludedXx_NEWLINE_xXDisease site/type with pathologic confirmation of diagnosis at participating cancer site; Note: if recurrence occurred greater than two years after resection, a biopsy to confirm recurrence should be performed and used for confirmation of diagnosis at the participating site\r\n* Phase 1: Advanced, unresectable sarcoma (any subtype, except for patients with pigmented villonodular synovitis for which metastatic disease is required)\r\n* Phase 2: Advanced, unresectable malignant peripheral nerve sheath tumors (MPNSTs)Xx_NEWLINE_xXSevere infection considered by the local site investigator to be unsafe for study participation.Xx_NEWLINE_xXParticipants must have histologically confirmed well differentiated or moderately differentiated neuroendocrine tumor from either a primary or metastatic site; carcinoid tumors of any primary site are eligibleXx_NEWLINE_xXPrior chemoembolization of local ablative therapies are allowed, provided there is measurable disease outside of the area treated, or documented evidence of progression at the site of prior treatmentXx_NEWLINE_xXPrimary disease site must be able to be treated with curative intentXx_NEWLINE_xXParticipants who have had radiotherapy to the site to be treatedXx_NEWLINE_xXHas measureable disease by RECIST 1.1 criteria as assessed by the local site investigator/radiology.Xx_NEWLINE_xXA pretreatment research core biopsy of the primary tumor must be performed with submission of 2 cores for required correlative studies. These specimens will NOT be returned to the site.Xx_NEWLINE_xXScheduled to receive a continuous course of fractionated, conventional external beam with a cumulative radiation dose between 55 and 72 Gy at each siteXx_NEWLINE_xXPatients must have radiographically measurable disease (as per Response Evaluation Criteria in Solid Tumors version 1.1 [RECISTv1.1]) in at least one site not previously treated with radiation or liver directed therapy (including bland, chemo- or radio-embolization, or ablation) either within the liver or in a metastatic siteXx_NEWLINE_xXAt least 3 weeks must have elapsed from prior radiation therapy; the prior site of radiotherapy must be documented as reirradiation of the same site is not allowed in this protocolXx_NEWLINE_xXParticipants who are involved in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXParticipants with involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXInvestigational site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study.Xx_NEWLINE_xXHas a history of re-irradiation for squamous cell carcinoma of the head & neck (SCCHN) at the projected injection site.Xx_NEWLINE_xXHas a tumor(s) in direct contact or encases a major blood vessel, and has ulceration and/or fungation onto the skin surface at the projected injection site.Xx_NEWLINE_xXWillingness and ability of participants to use the electronic device to report selected study outcomes; Caregivers and site staff can assist with patient diary input but patient must be able to independently comprehend and answer the questionnairesXx_NEWLINE_xXInvolvement in study planning and conduct (i.e., Hansoh staff or staff at the study site).Xx_NEWLINE_xXPhase I: Patients with a site of disease amenable to biopsy, and willing to undergo a new tumor biopsy at screening, and during treatment.Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment in the present studyXx_NEWLINE_xXWillingness to undergo biopsy of metastatic site or site of unresectable disease prior to randomizationXx_NEWLINE_xXPatient may not have disease limited to a single skin or bone site, with the following exceptions:\r\n* Central nervous system (CNS) risk lesions/special site disease: patients with single bone sites that are CNS-risk (sphenoid, mastoid, orbital, zygomatic, ethmoid, maxillary, or temporal bones, the cranial fossa, pituitary gland or neurodegenerative disease) or are “special sites” (odontoid peg, vertebral lesion with intraspinal soft tissue extension) require systemic therapy as standard of care and thus ARE eligible for the study\r\n* Functionally critical lesions: a single lesion not described above which may cause “functionally critical anatomic abnormality” wherein attempts at local therapy (such as surgical curettage or radiation) would cause unacceptable morbidity; these patients may be enrolled with approval of the principal investigator (PI) and documentation of the rationale justifying systemic therapyXx_NEWLINE_xXXRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.Xx_NEWLINE_xXDisease at the nasopharyngeal, sinus, oral cavity, or other sub-site not specifiedXx_NEWLINE_xXPrior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least 3 weeks prior to enrollment; if the irradiated area is the only site of disease, there will be progressive diseaseXx_NEWLINE_xXMale patients must use a form of barrier pregnancy prevention approved by the investigator / treating physician during the study and for at least one month after treatment discontinuation (site-specific criteria applying to Avera only)Xx_NEWLINE_xXNeg pregnancy test Part A extension only: • Has a primary tumor or a metastatic site that is accessible for pre- and post-dose biopsy without subjecting patient to high level of risk Part B only:Xx_NEWLINE_xXLife expectancy ?3 years, as judged by the site investigatorXx_NEWLINE_xXPrior radiation therapy is allowed as long as the irradiated area was not the sole source of measurable disease and radiotherapy was completed with recovery from toxicity, at least three weeks prior to enrollment; if the irradiated area is the only site of disease, there must be evidence of progressive diseaseXx_NEWLINE_xXPHASE IB: Patients in the expansion cohort must have a measurable site of disease according to RECIST (v 1.1) that has not been previously irradiated, or evidence of at least 20% progression in a previously irradiated lesion, and assessed by imaging within 28 days prior to registration for protocol therapyXx_NEWLINE_xXAt least one site of measurable disease in subjects with solid tumors and NHL.Xx_NEWLINE_xXSubject in whom the anatomic site is equal to or less than 25cm²;Xx_NEWLINE_xXSubject in whom the anatomic application site is equal to or less than 47cm²; andXx_NEWLINE_xXAt least one extracranial measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiation.Xx_NEWLINE_xXWilling to travel to a radioimmunotherapy site for Zevalin, if necessaryXx_NEWLINE_xXPatients with metastatic SCCA neck disease with an unknown primary tumor siteXx_NEWLINE_xXPatients may have had or may have a metastasis from a cutaneous primary site, mucosal primary site, or unknown primary site.Xx_NEWLINE_xXDisease confined to locoregional site and can be encompassed in a stereotactic body radiosurgery “portal”Xx_NEWLINE_xXAny of the following ECG findings or assessments including: Baseline QTcF interval >=450 milliseconds; Clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry.Xx_NEWLINE_xXHistologically proven recurrent/metastatic squamous cell carcinoma arising from a previous head and neck primary site, and located within the head and neck region, lung or bone, and who are not candidates for curative intent therapyXx_NEWLINE_xXMust have at least one tumor site accessible for a biopsyXx_NEWLINE_xXTumor tissue from an unresectable or metastatic site of disease must be provided for biomarker analysesXx_NEWLINE_xXRadiographic, biochemical, or clinical evidence of tumor progression over a period of up to 12 months in at least one siteXx_NEWLINE_xXPatients must agree to have a biopsy of metastatic tissue at baseline and on-treatment, and there must be a lesion that can be biopsied with acceptable clinical risk (as judged by the investigator)\r\n* Patients with unsuccessful baseline biopsies may undergo an additional biopsy attempt (at the same or a different site, determined by the investigator)\r\n* For patients with an intact primary and no metastatic site that can be safely biopsied, biopsy of the primary is acceptable, but must be approved by the principal investigatorXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both investigator staff and/or staff at the study site)Xx_NEWLINE_xXPatients must not have had prior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.Xx_NEWLINE_xXFor patients with oropharyngeal primary site or unknown primary site only: tumoral human papillomavirus (HPV) status must be known, as established by the local site; acceptable standards include p16 immunohistochemistry (where a tumor is classified as p16-positive when showing diffuse nuclear and cytoplasmic staining in at least 70% of tumor cells) and/or assessment of HPV deoxyribonucleic acid (DNA)Xx_NEWLINE_xXNasopharyngeal primary site, if WHO type III (non-keratinizing and EBV-positive as established at the local site)Xx_NEWLINE_xXThe subject has received therapeutic radiation:\r\n* To the bladder/prostate/rectum pelvis\r\n* To any other site(s) within 28 days of the first dose of study treatmentXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to AstraZeneca and/or Sarah Cannon Development Innovations staff and/or staff at the study site).Xx_NEWLINE_xXPatients must have at least one site of disease that is accessible for intratumoral injection of SD-101 (diameter >= 10 mm), percutaneouslyXx_NEWLINE_xXPatients must have at least one site of measurable disease, other than the injection site, which is not included in the radiation fieldXx_NEWLINE_xXCandidate for local consolidation therapy to at least one site of diseaseXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPatients must have documented IDH1-R132 gene-mutated disease as evaluated by the siteXx_NEWLINE_xXOngoing use of anticoagulant therapy other than aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) that places the participant at increased bleeding risk in the opinion of the site investigatorXx_NEWLINE_xXPrior oncologic (radical) surgery to the primary siteXx_NEWLINE_xXConcomitant radiation treatment to primary prostate siteXx_NEWLINE_xXWilling to undergo core needle biopsy of liver metastatic site.Xx_NEWLINE_xXThree or fewer total sites of active disease (at least one site of active disease to be treated on study must be confined to the abdomen or pelvis excluding liver and must be < 5 cm in greatest dimension as determined by pre-screening cross-sectional imaging)Xx_NEWLINE_xXAdditional site(s) of active disease (such as parenchymal liver and lung metastases, or supraclavicular nodal metastases), should be considered for treatment (off study) with radiation, surgery, or another form of local therapy, at the discretion of the study principal investigator (PI)Xx_NEWLINE_xXPatients with concomitant Gleason score 3+3 prostate cancer in less than 50% of any core at any site will be considered eligible.Xx_NEWLINE_xXMen who will receive radical prostatectomy to the primary siteXx_NEWLINE_xXActive infection at the site to be irradiatedXx_NEWLINE_xXPathology review at Monroe Dunaway (MD) Anderson (Note: if patient’s prostate biopsy was not read at MD Anderson, it must be reviewed at the study site to confirm eligibility).Xx_NEWLINE_xXPatients will have 6 or less extracranial sites, which can safely receive SBRT between 30 – 50 Gy in 5 fractions; a site may have multiple tumor lesions within it as long as the gross tumor volume (GTV) of the site is 8 cm or less and can be covered in an acceptable SBRT field determined by the principal investigator (PI); all gross disease must be amenable to treatment with SBRT, as allowable per normal tissue constraints; patients will not have had any prior radiation therapy significantly overlapping a tumor site to be treatedXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at MD Anderson).Xx_NEWLINE_xXTarget lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that site.Xx_NEWLINE_xXTortuosity preventing the delivery of the guide sheath and or RenovoCath™ catheter to intended site as determined by CT or MRIXx_NEWLINE_xXReport worst pain score ?4/10 at the target treatment site within the past 24 hoursXx_NEWLINE_xXHistologic proof or unequivocal cytologic proof of solid tumor malignancy; this may be obtained from either the primary or any metastatic siteXx_NEWLINE_xXCarcinoma of the neck of unknown primary site origin (even if p16 positive)Xx_NEWLINE_xXGross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident diseaseXx_NEWLINE_xXHave at least one site of lymphomatous disease amenable to external beam radiation therapy (EBRT)Xx_NEWLINE_xXPatients with liver tumors in a location that would potentially result in significant clinical adverse effects in the opinion of investigator if post-treatment tumor swelling were to occur, including at the site of the common bile ductXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site), previous enrollment in the present study.Xx_NEWLINE_xXPathological diagnosis of any solid tumor histology (from any site in the body)Xx_NEWLINE_xXPrevious use of radiation to metastatic site(s) at any time prior to enrollment is allowed, provided that this site is not the only measurable disease present or unless that solitary site is progressing following radiationXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to staff at the study site) or previous enrollment in the present studyXx_NEWLINE_xX1-3 sites of recurrence (< 60 cc per site, total volume < 100 cc)Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPrimary tumors of any head and neck (oral cavity, oropharynx, hypopharynx, or larynx) site will be includedXx_NEWLINE_xXInvestigator site staff members directly involved in the conduct of the study and their family members, site staff members otherwise supervised by the investigator, or patients who are Pfizer employees, including their family members, directly involved in the conduct of the study.Xx_NEWLINE_xXPrimary site other than oropharynxXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPatients with thrombosis of the planned site of resection will not be excluded if the thrombus is caused directly by tumor burden or outflow obstructionXx_NEWLINE_xXPatients with extramedullary disease as their sole site of relapsed AML.Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXUnidentifiable primary siteXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXClinically active infection (>= grade 2) as judged by the site investigatorXx_NEWLINE_xXPrior chemotherapy or immunotherapy will be allowed if new or persistent measurable site(s) of disease are presentXx_NEWLINE_xXIs or has an immediate family member (e.g., spouse, parent/legal guardian, sibling, or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subjectXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPrior therapy to a metastatic siteXx_NEWLINE_xXHistological confirmation of malignant carcinoma/sarcoma (any site) with metastasis to lung; histologic confirmation of the lung metastasis is not required providing there has been pathologic confirmation of malignancyXx_NEWLINE_xXAll patients must have no more than 3 contiguous vertebral body levels treated at a single site, and no more than 3 discontiguous vertebral body levels treatedXx_NEWLINE_xXAll patients must have radiographic evidence of progression at a spinal site previously irradiated greater than 6 months prior to randomization; this includes indirect radiation exposure to spinal siteXx_NEWLINE_xXAll patients must have a vertebral body site to be treated located from T1 to L5Xx_NEWLINE_xXPrior radiation at the site of interest within 6 monthsXx_NEWLINE_xXPrior history of radiation at the site of interest resulting in a critical neural tissue dose of EQD2/2 of > 42 Gy in a single sessionXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPathologic diagnosis of malignant mesothelioma (any primary site is acceptable, any histology is acceptable)Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) or previous enrollment in the present studyXx_NEWLINE_xXPatients with nasopharynx or salivary gland primary siteXx_NEWLINE_xXPatients who are to undergo definitive chemoradiation must have clinically or radiographically evident measurable disease at the primary site and/or at nodal stations. Tonsillectomy or local excision of the primary without removal of nodal disease is permitted.Xx_NEWLINE_xXSubjects must not be or have an immediate family member (spouse, parent, legal guardian, sibling or child) who is an investigational site sponsor or staff directly involved with the trial, unless IRB approval is granted previouslyXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment in the present studyXx_NEWLINE_xXMust be treated per protocol to lesion(s) of a single abdominal site that can reasonably be encompassed within a single treatment field; treatment of additional site(s) outside of the abdomen while the patient is on trial is acceptableXx_NEWLINE_xXPatients must be willing to travel to the study site for follow-up visitsXx_NEWLINE_xXSubjects must have at least one site of disease that is accessible for intratumoral injection of SD-101 (diameter >= 10 mm), percutaneouslyXx_NEWLINE_xXSubjects must have at least one site of measurable disease other than the injection site which is not included in the radiation fieldXx_NEWLINE_xXIs or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor-investigator staff directly involved with this trial, unless prospective Institutional Review Board [IRB] approval (by chair or designee) is given allowing exception to this criterion for a specific subjectXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site) or previous enrollment in the present studyXx_NEWLINE_xXPathologically–confirmed small cell carcinoma of any primary siteXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment in the present studyXx_NEWLINE_xXPatients must have a histologically confirmed solid tumor that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective; additionally, in the opinion of the investigator the primary site of the metastatic or unresectable tumor must have arisen within a previously irradiated site and be considered a radiation-induced tumorXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrolment in the present studyXx_NEWLINE_xXPatients who are investigational site staff members directly involved in the conduct of the trial, and their family members, site staff members otherwise supervised by the investigator, or patients who are Archigen employees directly involved in the conduct of the trial.Xx_NEWLINE_xXPrior therapy with gamma knife or other focal high-dose radiotherapy is allowed, but the patient must have subsequent histologic documentation of recurrence, unless the recurrence occurs remote from the treated siteXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrolment or randomization in the present studyXx_NEWLINE_xXRefractory or recurrent retinoblastoma with vitreous seeding meeting eligibility criteria by ultrasonic biomicroscopy performed during examination under anesthesia (EUA) by an ophthalmologist: \r\n* At least three consecutive clock hours of disease-free, attached peripheral retina through which the intraocular injection may be administered\r\n* Absence of invasion in anterior and posterior chamber\r\n* Absence of anterior hyaloid detachment\r\n* Absence of retinal detachment at the entry site\r\n* Absence of tumor at the entry siteXx_NEWLINE_xXPatients with an outside primary site biopsy showing perineural or perivascular invasionXx_NEWLINE_xXPathologic diagnosis of metastatic renal cell carcinoma (RCC) with clear cell component with progression or intolerance to at least one prior systemic anti-angiogenic therapy (if a previous biopsy of metastatic site within the last 12 months exists and a review of stained slides shows it to be adequate then a pretreatment biopsy is not required)Xx_NEWLINE_xXNasopharyngeal primary siteXx_NEWLINE_xXAt least 1 lesion amenable for outpatient biopsies; this should be a cutaneous or palpable metastatic site or a deeper site accessible by image-guided biopsy that is deemed safe to access by the treating physicians and interventional radiologists; patients without accessible lesions for biopsy but with prior tissue available from metastatic disease would be eligible at the investigator’s discretionXx_NEWLINE_xXMagnetic resonance (MR) imaging of the brain (performed within 14 days of enrollment) must demonstrates no evidence of diffuse leptomeningeal spread beyond the primary relapse site in posterior fossa and no obstruction of cerebrospinal fluid flow (CSF)Xx_NEWLINE_xXPHASE II SCLC: Patients could have received any number of therapies for relapsed or progressive disease, including re-treatment with original frontline regimen; a minimum of 2 weeks will be required from any prior therapy, including chemotherapy, immunotherapy and/or radiation; in addition, recovery to grade =< 1 from all reversible toxicities related to prior therapy is required at study entry; no previous irradiation to the site of measurable or evaluable disease, unless that site had subsequent evidence of progressionXx_NEWLINE_xXAt least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma (Cheson Criteria); the site of disease must be greater than 1.5 cm in the long axis regardless of short axis measurement or greater than 1.0 cm in the short axis regardless of long axis measurement, and clearly measurable in 2 perpendicular dimensionsXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXConsultation with a medical oncologist at enrolling site =< 56 days prior to registration, with determination that treatment with neoadjuvant chemoradiotherapy with weekly carboplatin and paclitaxel is considered acceptableXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPrior therapy to a metastatic siteXx_NEWLINE_xXThe vertebral body site to be treated must be located from the second to the twelfth thoracic vertebrae (T2-T12)Xx_NEWLINE_xXPrior conventional radiation to the same site is allowed as long as there is a greater than 3 months intervalXx_NEWLINE_xXPrior conventional irradiation of the spine site and level to be treated with an interval shorter than 3 monthsXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPatient may have more than one site of recurrent or metastatic disease but only one lesion that is >= 1 cm in size will be injected (if in the lung, the lesion must be >= 2 cm and adjacent to the pleura in the lung)Xx_NEWLINE_xXPatients may have either metastatic lesions from another primary site or primary hepatocellular carcinoma; patients with one histologically confirmed metastatic lesion of the liver who are presenting for local therapy for lesions concerning for metastases that cannot or should not be biopsied will also be considered for enrollment on a case by case basis; patients can simultaneously receive treatment for multiple hepatic lesions meeting the prior two requirements, at the discretion of the treating radiation oncologistXx_NEWLINE_xXSigns of wound-healing problems or infection at the craniotomy/biopsy site.Xx_NEWLINE_xXTreatment plan must include primary site biopsy followed by resection of the primary tumor site and any metastatic sites at time of surgeryXx_NEWLINE_xXUnresectable adenocarcinoma of the breast involving chest wall, regional nodes, or distant siteXx_NEWLINE_xXPatient is unable to have a biopsy of a metastatic site for Rb testingXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment or randomization in the present studyXx_NEWLINE_xXPatients who are involved in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment or randomization in the present studyXx_NEWLINE_xXPresence of overt metastatic disease at any siteXx_NEWLINE_xXPatients with residual tumor after surgery (any single site) exceeding 1 cm in maximum dimension.Xx_NEWLINE_xXAt least one measurable disease site that meets target lesion requirementsXx_NEWLINE_xXNot willing to stay at the study site for 4 hours after each PRTX-100 infusionXx_NEWLINE_xXPrimary site of tumor of oral cavity, nasopharynx, sinuses, or salivary glandsXx_NEWLINE_xXInitial surgical treatment including tonsillectomy or neck dissection, but excluding diagnostic biopsy of the primary site or nodal sampling of neck diseaseXx_NEWLINE_xXAccessibility to the site that ensures the subject will be able to keep all study-related appointments.Xx_NEWLINE_xXThe biopsy site must have been demarcated by a clip(s)Xx_NEWLINE_xXCOHORT II: The biopsy site must have been demarcated by a clip(s)Xx_NEWLINE_xXMIBG scan with positive uptake at minimum of one siteXx_NEWLINE_xXXRT: At least 14 days since the last treatment except for radiation delivered with palliative intent to a non-target site.Xx_NEWLINE_xXPatients who have received prior radiation to the head and neck or adjacent anatomical site (e.g., upper lobe lung, brain)Xx_NEWLINE_xXPrior radiation to the site of current primary disease, if re-treatment would lead to violation of known radiation dose tolerance limits for that siteXx_NEWLINE_xXFor patients with a new diagnosis of melanoma treated in cohort 2 who have a cutaneous primary, the primary site may be addressed surgically (wide local excision; skin grafting) prior to the initiation of ipilimumab and radiation at the discretion of the treating surgeonXx_NEWLINE_xXPatients must have at least one site of disease that is accessible for intratumoral injection percutaneously (e.g. inguinal, axillary, cervical, or subcutaneous)Xx_NEWLINE_xXPatients must have measurable disease other than the injection site or biopsy site, i.e. greater than 1.5 cm bi-dimensionally on standard computed tomography imagingXx_NEWLINE_xXPatients with any number of metastatic site are allowed to enroll; however, only up to six sites will be selected for SBRT treatment, at the discretion of the treating radiation oncologistXx_NEWLINE_xXSubjects who have been diagnosed with prior cancer at any site may participate as long as they have been off medical therapy for at least one yearXx_NEWLINE_xXAt least 1 lesion amenable for an outpatient biopsy; this should be a cutaneous or palpable metastatic site or a deeper site accessible by image-guided biopsy that is deemed safe to access by the treating physicians and interventional radiologists; patients without accessible lesions for biopsy but with prior tissue available from metastatic disease would be eligible at the investigator's discretionXx_NEWLINE_xXPatient must consent to a biopsy of a site of disease unless the only site of disease is lung/pleura, bone, or deemed unsafe by the principal investigatorXx_NEWLINE_xXAll patients must have histological proof of malignant cancer, which is metastatic; histological proof may be obtained from the primary tumor or another metastatic site; however, cytology alone is not an acceptable method of diagnosisXx_NEWLINE_xXPatients who had previous radiation dose to the site of the current primary disease, which would lead to violation of known radiation tolerance limit of that particular site if treated againXx_NEWLINE_xXHistologically documented metastatic or surgically unresectable urothelial carcinoma; may include primary site from ureters, upper tract, renal pelvis, and bladder.Xx_NEWLINE_xXPhase II cohorts only: Patients must have a site of disease amenable to biopsy, and be a candidate for tumor biopsy according to the treating institution's guidelines. Phase Ib patients need not have disease accessible to biopsyXx_NEWLINE_xXPatients with any evidence of damaged skin, or moles, scars, tattoos or marks at the proposed site(s) of administration that might interfere with the interpretation of local skin reactions.Xx_NEWLINE_xXHistory or evidence of a physician-diagnosed chronic or recurrent inflammatory skin disease (e.g. psoriasis, eczema, atopic dermatitis, hypersensitivity) at the proposed site of administration in the past 5 years.Xx_NEWLINE_xXPatients with prior fractionated radiation to the treated site are allowed; their prior treatment plan with date, fractionation, dose and treatment fields must be obtained; there must be at least a three month interval elapsed from the prior radiation to the treated site and enrollmentXx_NEWLINE_xXIs or has an immediate family member (example, spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subject.Xx_NEWLINE_xXApparent tumor invasion into organs located adjacent to the esophageal disease site (eg, aorta or respiratory tract) at an increased risk of fistula in the study treatment assessed by investigatorXx_NEWLINE_xXAll patients with histologic proof of malignant melanoma. Histologic confirmation may be from the primary tumor site, or from another metastatic site (systemic lymph node, etc). Cytology-alone is not an acceptable method of diagnosis.Xx_NEWLINE_xXAt least one site of measurable disease as defined by at least 1 cm in greatest dimension; this site must be different from the sites to be used for biopsy; no prior radiation therapy or directed ablation to the site of measurable diseaseXx_NEWLINE_xXTargeted tumor is at an impending fracture site of the weigh bearing bone (>7 on fracture risk score, see Section 6.9). OR o Patients with surgical stabilization of tumor site with metallic hardwareXx_NEWLINE_xXThe targeted tumor(s) is (are) less than 2 points more painful compared to other non-targeted painful lesions on the site specific NRS.Xx_NEWLINE_xXSubject must have a bloodstream infection with no other apparent source that is not related to an infection at another site that meets one of the following:Xx_NEWLINE_xXSubjects with the presence of a tunnel or catheter exit site infection or an infusion port pocket abscess as manifested by purulence at the exit site, or inflammation with erythema, or induration of greater than 1 cm in diameter;Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).Xx_NEWLINE_xXsafety of study staffXx_NEWLINE_xXMeasurable disease according to RECIST v1.1, and willingness to undergo a total of 2 biopsies of a primary or metastatic tumor site(s) considered safely accessible for biopsy.Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPatients must have evidence of MIBG uptake into tumor at >= one site within 4 weeks prior to entry on study and subsequent to any intervening therapyXx_NEWLINE_xXPatients must not have received radiation for a minimum of two weeks prior to start of vorinostat; for patients with only one site of measurable or evaluable disease, radiation must not have been given to that site unless that site has demonstrated clear progression after radiationXx_NEWLINE_xXIs or has an immediate family member (spouse or children) who is investigational site or staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subjectXx_NEWLINE_xXRENAL COHORT: If the kidney primary tumor is in place this is the preferred site of biopsyXx_NEWLINE_xXFewer than two acceptable sites exist for intramuscular (IM) injection and electroporation (EP) between the deltoid and lateral quadriceps muscles. Note: a site for injection/EP is not acceptable if there are tattoos or scars within 2 cm of the proposed injection/EP site or if there is implanted metal within the same limb. Any device implanted in the chest (e.g. cardiac pacemaker or defibrillator) excludes the use of the deltoid muscle on the same side of the body.Xx_NEWLINE_xXPatients must have an archival sample of tumor or metastatic site core biopsy to be eligibleXx_NEWLINE_xXParticipant is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is an investigational site or sponsor-investigator staff directly involved with this trial, unless prospective IRB approval (by chair or designee) is granted allowing exception to this criterion for a specific subjectXx_NEWLINE_xXHave at least 1 of the tumor sites that must be amenable to core needle biopsy and this may not be the site of disease used to measure antitumor responseXx_NEWLINE_xXHistological evidence of primary stage III or IV or recurrent endometrial carcinoma who have had definitive surgery for endometrial cancer (at least hysterectomy and bilateral salpingo-oophorectomy); pathologic documentation of the recurrence (i.e., biopsy) is required if there is only a single site of disease on imaging and that site is less than 2 cm; if a subject with recurrence is undergoing a biopsy for clinical indications and is willing and able, an optional collection of 3 frozen tissue cores of the recurrence site is requested for correlative analysisXx_NEWLINE_xXThe patient must have measurable disease according to RECIST v1.1 and must have one site amenable to biopsy that, in the opinion of the investigator and/or interventional radiologist, is likely to yield acceptable tumor sample for a core biopsy per the below pathology criteriaXx_NEWLINE_xXAvailability of a representative tumor specimen from a site not previously irradiated that is suitable for determination of programmed death-ligand 1 (PD-L1) status via central testingXx_NEWLINE_xXPrior therapy with a conjugated or unconjugated auristatin derivative/vinca-binding site targeting payload.Xx_NEWLINE_xXPatients must have biopsy-proven adenocarcinoma of the small bowel at any site (duodenum, jejunum, ileum), excluding ampullary and appendiceal tumorsXx_NEWLINE_xXCarcinoma of the neck of unknown primary site origin (even if p16-positive).Xx_NEWLINE_xXGross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease. Patients with RECIST, v. 1.1 evaluable remaining cancer either in the neck or primary site remain eligible.Xx_NEWLINE_xXHave measurable disease outside of biopsy site present per immune related (ir)RECIST criteriaXx_NEWLINE_xXPatients must have disease refractory to standard therapy or recurrent malignancy; patient’s current disease state must be one for which no known curative therapy is available; to be eligible for phase I study patients should have primary refractory or relapsed disease as evidenced by either:\r\n* Local or/and metastatic tumor recurrence or primary refractory tumor measurable on CT or magnetic resonance imaging (MRI) scans\r\n* Refractory persistent bone marrow disease with evidence of NB involvement of bone marrow in at least one site of biopsy\r\n* NB with metaiodobenzylguanidine (MIBG)-positive skeletal lesions (at least one site)\r\n* For sarcoma patients with resected pulmonary lesions pre-surgery CT scans demonstrating disease are requiredXx_NEWLINE_xXPatient may have more than one site of recurrence/metastatic disease but only one lesion will be injected that is >= 1 cm in size (if in the lung, the lesion must be >= 2 cm and adjacent to the pleura in the lung)Xx_NEWLINE_xXPatients who have measurable residual tumor at the primary siteXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment in the present studyXx_NEWLINE_xXSubmission of tumor tissue is required for all patients; investigators should check with their site pathology department regarding release of biospecimens before approaching patients about participation in the trialXx_NEWLINE_xXHave at least one site of disease that is considered potentially suitable for treatment with SBRTXx_NEWLINE_xXPatients must have a histologic diagnosis of melanoma either from a primary or metastatic site; patients with brain metastases must have completed radiation therapy > 30 days prior to enrollmentXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and staff at University of Iowa Hospitals and Clinics [UIHC])Xx_NEWLINE_xXPatients who have received prior surgical site radiationXx_NEWLINE_xXMeasurable disease per modified (m)RECIST version (v)1.1; patients must have at least 1 distinct site of measurable disease, >= 1 cm in its largest diameter, in addition to the site that is being irradiatedXx_NEWLINE_xXPatients with nasopharyngeal, paranasal sinus, skin, or unknown primary site diseaseXx_NEWLINE_xXIs or has an immediate family member (spouse or children) who is investigational site or sponsor staff directly involved with this study, unless prospective institutional review board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific subjectXx_NEWLINE_xXPatients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations; tonsillectomy or local excision of the primary without removal of nodal disease is permitted, as is excision removing gross nodal disease but with intact primary site; limited neck dissections retrieving =< 4 nodes are permitted and considered as non-therapeutic nodal excisionsXx_NEWLINE_xXCarcinoma of the neck of unknown primary site origin (even if p16 positive)Xx_NEWLINE_xXGross total excision of both primary and nodal disease with curative intent; this includes tonsillectomy, local excision of primary site, and nodal excision that removes all clinically and radiographically evident disease; in other words, to participate in this protocol, the patient must have clinically or radiographically evident gross disease for which disease response can be assessedXx_NEWLINE_xXPHASE II: The patient meets the criteria required for the imaging study in which the site is participating:\r\n* NOTE: Eligibility for participating in either imaging sub-study will depend on the availability of the imaging sub-study at a particular institution\r\n* For participation in the FDG-PET sub-study:\r\n** Patients must NOT have poorly controlled diabetes (defined as fasting glucose level >= 200 mg/dL) despite efforts to improve glucose control by fasting duration and adjustment of medications\r\n** Patient must NOT weigh more than the maximum weight limit for the PET table\r\n** Patients must have an evaluable lesion of > 20 mm in size on standard practice imaging study as assessed by site (either primary pancreas mass or metastasis)\r\n* For participation in the FLT-PET sub-study:\r\n** Patients must be able to lie still for a 1.5 hour PET scan.\r\n** Patient must NOT have a history of allergic reaction attributable to compounds of similar chemical or biologic composition to 18F-fluorothymidine\r\n** Patient must NOT weigh more than the maximum weight limit for the PET table\r\n** Patients must have an evaluable lesion in the pancreas > 20 mm in size on standard practice imaging study as assessed by site (lesion must be likely primary adenocarcinoma of the pancreas that is not primarily fibrotic or mucinous in nature)Xx_NEWLINE_xXPrimary disease site involving the oropharynxXx_NEWLINE_xXAny head and neck subsite other than oropharynx (including unknown primary site)Xx_NEWLINE_xXPatient agrees to stay within a reasonable distance (i.e. 30 minutes travel time) of the study site for the duration of the first treatment cycle through 24 hours after the last doseXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXPatients by definition have disease at the primary tumor site of at least 2 centimetersXx_NEWLINE_xXPatient’s treatment plan must include primary tumor site biopsy followed by gross excision of the primary tumor site at a separate operative procedureXx_NEWLINE_xXPrevious radiosurgery to any intracranial site within the prior 6 weeksXx_NEWLINE_xXHistologic diagnosis of resected stages IIIC/ IV melanoma, with no evidence of disease clinically and radiologically; all melanomas regardless of primary site of disease will be allowedXx_NEWLINE_xXPatients must have evidence of MIBG uptake into tumor at ? one site within 4 weeks prior to entry on study and subsequent to any intervening therapy.Xx_NEWLINE_xXAll patients must have at least ONE site of evaluable disease.Xx_NEWLINE_xXPatients at initial presentation of melanoma must undergo an adequate wide excision of the primary lesion, if present; patients with previously diagnosed melanoma must have had all current disease resected with pathologically negative margins and must have no evidence of disease at the primary site or must undergo re-resection of the primary site; a full lymphadenectomy meeting the criteria outlined is required for all node-positive patients including those with positive sentinel nodes; patients with recurrent disease who have had a prior complete lymphadenectomy fulfill this requirement as long as all recurrent disease has been resected; for all patients, all disease must have been resected with negative pathological margins and no clinical, radiologic, or pathological evidence of any incompletely resected melanoma; patients must be registered within 98 days of the last surgery performed to render the patient free of diseaseXx_NEWLINE_xXNon-CNS site of radiation must be completed > 2 weeks prior to CTL019 infusionXx_NEWLINE_xXPatients presenting with metachronous disease may have distant metastases, regional lymph node or renal bed recurrence; recurrences at a partial nephrectomy resection site are not eligible if it is the only site of diseaseXx_NEWLINE_xXSubject with a BMI ?50, which may interfere with access to the surgical site and increase overall operative risk.Xx_NEWLINE_xXSubject with an active abdominal or pelvic infection at the operation site.Xx_NEWLINE_xXCarcinoma of the neck of unknown primary site origin (regardless of HPV/p16 status) is eligibleXx_NEWLINE_xXDisease must be considered incurable; incurable is defined as metastatic disease or a local or regional recurrence in a previously irradiated site that is unresectable (or patient declines resection)Xx_NEWLINE_xXMedically appropriate candidate for radical nephroureterectomy or ureterectomy as per MSKCC or a participating site attending urologic oncologistXx_NEWLINE_xXsafety of study staffXx_NEWLINE_xXThe patient must be accessible for scheduled visits, treatment and follow-up. Patients registered on this trial must be treated at the participating center which could be the Principal or a Co- investigator's site.Xx_NEWLINE_xXMust have an apheresis product of non-mobilized cells received and accepted by the manufacturing site.Xx_NEWLINE_xXPatients planning to enroll in the phase I portion of this study must first have a slot reserved in advance of the registration; all site staff will use OPEN to create a slot reservation\r\n* NOTE: Phase I is closed to accrual effective 4/1/15Xx_NEWLINE_xXSite has received notification from Mayo Clinic – Rochester Division of Hematopathology of the central confirmation of diagnosis and tissue adequacy for mandatory research studiesXx_NEWLINE_xXMeasurable disease as defined per RECIST v. 1.1. Tumor lesions previously irradiated or subjected to other locoregional therapy will only be deemed measureable if disease progression at the treated site after completion of therapy is clearly documented.Xx_NEWLINE_xXat least one bidimensionally measurable, PET positive disease site (transverse diameter of ?1.5 cm and perpendicular diameter of ?1.0 cm at baseline)Xx_NEWLINE_xXSubjects with any previously untreated or concurrent cancer that is distinct in primary site orXx_NEWLINE_xXPrevious chemotherapy for any other disease site if given within 3 years prior to step 1Xx_NEWLINE_xXHistologic diagnosis of resected stages IIIB/IIIC/IV melanoma, with no evidence of disease clinically and radiologically, and negative surgical margins; all melanomas regardless of primary site of disease will be allowedXx_NEWLINE_xXMetastatic renal cell carcinoma (clear cell or non clear cell)\r\n* One metastatic site amenable to cryoablation\r\n* Patients with a single metastatic site may be enrolled if that site is amenable to ablation; however these patients will not be counted in secondary measures of response unless there is new disease detected during follow up\r\n* Eligible for cytoreductive surgery, metastasectomy, or repeated biopsy; biopsy site cannot be lung, mediastinal lymph node, or bone (unless soft tissue component)Xx_NEWLINE_xXVertebral body site to be treated is located from C3 to L5Xx_NEWLINE_xXParticipants with MDS, CMML, or low blast AML, whose only site of disease is extramedullary, example, the skin.Xx_NEWLINE_xXPhase I run in: biopsy proven RMHNSCC with the following primary sites: nasopharynx, paranasal sinus, nasal cavity, skin/cutaneous sites; patients with unknown head and neck primary sites will be enrolled; patients with recurrent or metastatic squamous cell carcinomas of the head and neck (regardless of primary site) who are either unwilling to receive or have contraindications (deemed by treating physician) to standard systemic chemotherapy will also be eligible; patients with biopsy proven RMSGC be eligible as wellXx_NEWLINE_xXPhase II expansion: biopsy proven RMHNSCC, of any primary site (including unknown primary) and RMSGC will be eligibleXx_NEWLINE_xXAny primary site of urothelial carcinoma including upper tract, renal pelvis, bladder, and uretersXx_NEWLINE_xXPathologic diagnosis of malignant mesothelioma (any primary site is acceptable)Xx_NEWLINE_xXAt least 1 of the tumor sites must be amenable to core needle biopsy and this may not be the site of disease used to measure antitumor responseXx_NEWLINE_xXPrimary tumor site without progression at registrationXx_NEWLINE_xXProgression of primary tumor site (breast, prostate, or lung) at time of registrationXx_NEWLINE_xXPrevious or concomitant malignancies at any other site with the exception of the following:Xx_NEWLINE_xXImmediate family member who is investigational site or sponsor staff directly involved with this studyXx_NEWLINE_xXAt least 1 lesion amenable for outpatient biopsies; this should be a cutaneous or palpable metastatic site or a deeper site accessible by image-guided biopsy that is deemed safe to access by the treating physicians and interventional radiologists; patients without accessible lesions for biopsy but with prior tissue available from metastatic disease would be eligible at the investigator’s discretionXx_NEWLINE_xXPatients must have a site of metastatic disease that can be safely resected or biopsied for tissue sufficient for TIL harvestXx_NEWLINE_xXAt least 1 lesion amenable for outpatient biopsies; this should be a cutaneous or palpable metastatic site or deeper site accessible by image-guided biopsy that is deemed safe to access by the treating physicians and interventional radiologists; patients without accessible lesions for biopsy but with prior tissue available from metastatic disease would be eligible at the investigator's discretionXx_NEWLINE_xXMedically appropriate candidate for radical cystectomy, as per Memorial Sloan-Kettering (MSK) or participating site attending urologic oncologistXx_NEWLINE_xXHave at least one site of disease measurable disease by RECIST v1.1 that has not been treated with local therapy within 6 months of study treatment. This can be the site for initial or repeat biopsies as long as it will remain measurable following biopsy.Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).Xx_NEWLINE_xXMeasurable disease; Note: previously irradiated sites can be included if there is documented disease progression in that siteXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca, contract research organization [CRO] staff, and/or staff at the central processing unit [CPU])Xx_NEWLINE_xXAbility and agreement to attend protocol-specified visits at the study siteXx_NEWLINE_xXSubject has an active or suspected infection at the surgical site;Xx_NEWLINE_xXSubject in whom the investigational or control device will be used at the site of a valve replacement or repair;Xx_NEWLINE_xXSubject in whom the investigational or control device will be used at the site of a synthetic graft or patch implant;Xx_NEWLINE_xXSubject does not have an active or suspected infection at the surgical site;Xx_NEWLINE_xXSubject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation reversed prior to target bleeding site (TBS) identification and treatment;Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site); previous enrollment in the present studyXx_NEWLINE_xXAny of the following electrocardiogram (ECG) findings: Baseline QTcF >=450 millisecond (msec). NOTE: Any clinically significant ECG assessments should be reviewed by the site cardiologist prior to study entry.Xx_NEWLINE_xXParticipant is or has an immediate family member (spouse or children) who is investigational site or sponsor staff directly involved with this trial, unless prospective Institutional Review Board (IRB) approval (by chair or designee) is given allowing exception to this criterion for a specific participant.Xx_NEWLINE_xXTarget lesions may be located in a previously irradiated field if there is documented (radiographic) disease progression in that siteXx_NEWLINE_xXPatient has already undergone wide local excision at the site of the primary index lesion.Xx_NEWLINE_xXPlanned adjuvant radiotherapy to the primary melanoma site after Wide Local Excision is not permitted as part of the protocol and any patients given this treatment would be excluded from the study.Xx_NEWLINE_xXPatient is or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or Sponsor staff directly involved with this trial without prospective Institutional Review Board approval (by chair or designee) is givenXx_NEWLINE_xXNasopharyngeal primary site, if WHO type II or III (non-keratinizing)Xx_NEWLINE_xXMCL patients must have:\r\n* At least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma\r\n* Received at least 1 prior standard therapy for MCLXx_NEWLINE_xXPatients must be willing to travel to the study site for follow-up visitsXx_NEWLINE_xXPatients with nasopharynx or salivary gland primary site will be excluded from this trialXx_NEWLINE_xXCholangiocarcinoma subjects must have radiographically measurable disease in at least one site not previously treated with radiation, chemoembolization, radioembolization, or other local ablative procedures; a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptable.Xx_NEWLINE_xXSubjects must have radiographically measurable disease in at least one site not previously treated with radiation, chemoembolization, radioembolization, or other local ablative procedures; a new area of tumor progression within or adjacent to a previously-treated lesion, if clearly measurable by a radiologist, is acceptable.Xx_NEWLINE_xXPatients who previously received radiotherapy to the primary site with CT evidence of disease progression at the primary site within 3 months following the initial radiotherapyXx_NEWLINE_xXCOHORT A: The subject must have newly diagnosed prostate cancer with a metastatic site(s)Xx_NEWLINE_xXCOHORT A: The subject must be deemed medically fit for radical prostatectomy by the attending urologic surgeon at the selected study siteXx_NEWLINE_xXAt least 1 measurable site of disease according to Revised Response Criteria for Malignant Lymphoma 2007Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff, its agents and/or staff at the study site).Xx_NEWLINE_xXAt least one site of accessible disease for pre- and post-treatment core biopsies for at least 20 patients per arm on the expansion cohorts.Xx_NEWLINE_xXEnrollment in a concurrent cancer therapeutic trial will require prior review and approval by the study site principal investigator (PI) to determine that there are no drug interactions concernsXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).Xx_NEWLINE_xXSite of disease amenable to low-dose, local radiotherapy (2 x 2Gy)Xx_NEWLINE_xXsafety of study staffXx_NEWLINE_xXCRPC with metastatic disease with at least one site of metastatic disease must be amenable to needle biopsy; soft tissue biopsy sites include: lymph node or visceral metastases; bone sites include lumbar vertebrae, pelvic bones and long bones; excluded sites are thoracic, cervical vertebrae, skull and rib lesions; biopsy site will be selected with guidance of interventional radiologist determining best site to optimize balance of obtaining useful tissue for analysis and minimizing riskXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site).Xx_NEWLINE_xXAt least 1 measurable site of disease according to Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXPatients with multifocal or multicentric disease are eligible as long as each tumor individually meets eligibility criteria; central confirmation is needed for any site of disease that is tested to be HER2-positive by local testing (unless testing was done by Clarient)Xx_NEWLINE_xXTumor tissue from an unresectable or metastatic site of disease for biomarker analysesXx_NEWLINE_xXPatients must have histologic documentation or clinical evidence of a carcinoid tumor of primary site (including foregut, midgut, hindgut or other non-pancreatic site); tumors of unknown primary site are eligible provided the treating physician does not suspect medullary thyroid cancer, pancreatic neuroendocrine tumor, paraganglioma, or pheochromocytoma; unknown primary tumors will be classified as small bowel tumors for the purpose of stratification; functional (associated with a clinical syndrome) or nonfunctional tumors are allowed; target lesions must have shown disease progression if therapy included peptide receptor radiotherapy (PRRT) and PRRT must be completed at least 8 weeks prior to registrationXx_NEWLINE_xXPatient has at least one measurable lesion as defined by RECIST 1.1. A previously irradiated site lesion may only be counted as a target lesion if there is clear sign of progression since the irradiationXx_NEWLINE_xXHistologic documentation of well differentiated or moderately differentiated locally unresectable or metastatic pancreatic neuroendocrine tumor from either a primary or metastatic site with documented disease progression =< 12 months prior to enrollment with whose disease is not currently amenable to surgery, radiation or modality therapy with curative intent; if different histologic classification schemes are used, equivalent histologic classifications (for example “grade 1,” “low grade,” or “intermediate grade”) are allowed; there must be histologic documentation of a pancreatic primary site or clinical evidence of a pancreatic neuroendocrine primary tumor as determined by the treating physician; documentation from a metastatic site is sufficient if there is clinical evidence of a pancreatic primary site; in the case of discordant pathology, patient eligibility will be determined by the principal investigator (PI) after review of available records; patients with neuroendocrine tumors (e.g., gastrinoma, vasoactive intestinal peptidase [VIPoma]) in whom a pancreatic or peripancreatic primary site is strongly suspected are also eligibleXx_NEWLINE_xXGastric or duodenal ulcer (at least 10 mm in size) within 10 mm of expected endoscopy puncture site(s) for photodynamic therapy (PDT)Xx_NEWLINE_xXSTEP 2 ENROLLMENT AND RANDOMIZATION: the patient must be a suitable candidate for LCT (radiotherapy and/or surgery) to every site of disease, as determined by the treating physician(s); consultation with a multidisciplinary team, including a medical oncologist, radiation oncologist, and thoracic surgeon, is encouraged but not requiredXx_NEWLINE_xXPatients must have a tumor site amenable to biopsy as determined by the treating investigator; any questions regarding suitability of a site for biopsy will be adjudicated by the principal investigatorXx_NEWLINE_xXPatients with newly diagnosed PVNS with, at least, one measurable site of disease on MRI.Xx_NEWLINE_xXPrior irradiation of the spine site and level to be treatedXx_NEWLINE_xXDisease amenable to core biopsy; patients with pulmonary metastases as their only site of disease may enroll on this trial and will not undergo biopsyXx_NEWLINE_xXMedically appropriate candidate for radical cystectomy, as per MSKCC or participating site attending urologic oncologistXx_NEWLINE_xXNo prior chemoradiation to the primary pancreatic tumor unless there is a measurable distant site of diseaseXx_NEWLINE_xXPatients with an intact colon/rectum, except for clinical polyposis, and prophylactic surgery is being considered as a stratification site.Xx_NEWLINE_xXRectal/pouch polyposis as a stratification site as follows:Xx_NEWLINE_xXDuodenal polyposis as a stratification site; one or more of the following:Xx_NEWLINE_xXSubjects with mammographic appearance of overall dense parenchymal tissue may be included, as long as a clearly evident marker is present at tumor siteXx_NEWLINE_xXPatients enrolled based on tumor ER/PR status must have ER/PR status confirmed by the Laboratory of Pathology, National Institutes of Health (NIH); ER/PR status will be determined on a metastatic site, if possible; otherwise, the original site or available tissue will be acceptableXx_NEWLINE_xXIf patient has only one metastatic lesion/focus, this must be proven by biopsy and the pathology report confirming the diagnosis of primary breast cancer, as well as the metastatic site, must be availableXx_NEWLINE_xXLocal disease at the primary site must be asymptomaticXx_NEWLINE_xXOpen-label day 1 visit is within 6 months after this amendment is approved and becomes effective at the study site;Xx_NEWLINE_xXPatients cannot have more than 3 vertebrae or paraspinal sites involved (each involved vertebral body or paraspinal site is scored as 1 site of disease)Xx_NEWLINE_xXPRIMARY SITE (ONE OF THE FOLLOWING CRITERIA):Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXHas ?1 lesion that meets the criteria for measurable, as defined by RECIST 1.1, and is appropriate for selection as a target lesion, as determined by local site investigator/radiology assessmentXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applied to both AstraZeneca staff and/or staff at the study site); previous enrollment in the previous studyXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca Representative staff and/or staff at the study site);Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXEmployees of the clinical study site who are directly involved with the conduct of the study, or immediate family members of such individuals. These subjects may be treated at another site participating in the studyXx_NEWLINE_xXPrior radiation to site(s) of distant metastasis of boneXx_NEWLINE_xXBone as the only site of diseaseXx_NEWLINE_xXPatients who are investigational site staff members directly involved in the conduct of the trial and their family members, site staff members otherwise supervised by the Investigator, or patients who are Pfizer employees directly involved in the conduct of the trial.Xx_NEWLINE_xXAt least 1 measurable site of disease according to Revised Response Criteria for Malignant LymphomaXx_NEWLINE_xXPrimary tumors of the bone (e.g., osteosarcoma) at site of index vertebra(e),Xx_NEWLINE_xXBenign tumors of the bone (e.g. osteoid osteoma) at site of index vertebra (e),Xx_NEWLINE_xXRAS (KRAS/NRAS) wild type mCRC not previously treated with an anti-EGFR containing regimen (unless contraindicated or not considered standard practice per clinical site or country guidelines).Xx_NEWLINE_xXPrior or current evidence of any metastatic involvement of any distant siteXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXActive extramedullary disease at any site. (Note: Definitive therapy of known previous sites of extramedullary disease is allowed)Xx_NEWLINE_xXHemoglobin (Hb) > 9 g/dL or values >= lower limit of normal (LLN) for site-specific labXx_NEWLINE_xXPatients must have at least one site of disease that is accessible for intratumoral injection of SD-101 and of ipilimumab (diameter >= 10mm), percutaneouslyXx_NEWLINE_xXPatients must have measurable disease other than the injection site or biopsy siteXx_NEWLINE_xXPresence of >= 1 metastatic site (nodal, visceral) that is amenable to core biopsyXx_NEWLINE_xXSubject (and/or parent/guardian for subject who otherwise is unable to provide independent consent, if acceptable to and approved by the site and/or site's IRB) must be willing to give written informed consent and be able to adhere to dose and visit schedules.Xx_NEWLINE_xXPresence of clinically and/or radiologically documented disease. At least one site of disease (which will not be removed during the course of the study) must be uni-dimensionally measurable as per RECIST 1.1 or clinically quantifiable (such as in the case of skin disease)Xx_NEWLINE_xXHistology slides and pathology material must be available at the site for each patient before enrollment in order to be sent to the leading institution of the study for central pathology review and pharmacodynamic studiesXx_NEWLINE_xXPatients with unresectable or metastatic melanoma, for whom treatment with ipilimumab is indicated as per ipilimumab/Yervoy® package insert (applicable for US sites) or product information (applicable for Australia site).Xx_NEWLINE_xXAny contraindications for ipilimumab/Yervoy® as per package insert(applicable for US sites) or product information (applicable for Australia site).Xx_NEWLINE_xXAt least 2 sites of disease\r\n* One for palpable for biopsy and treatment (if > 2 sites are present, the biopsy site can be different from the treatment site); if there is no palpable disease, ultrasound may be used for guidance and administration of SD-101\r\n* One measurable radiographically or by skin assessmentXx_NEWLINE_xXPatients with smoking history of less than or equal to 10 pack years and with primary tumour site of base of tongue and/or tonsilXx_NEWLINE_xXERLOTINIB HYDROCHLORIDE ARM: Patients must have an EGFR tyrosine kinase inhibitor (TKI) sensitizing mutation as determined by analysis of the primary tumor or a metastatic site in a Clinical Laboratory Improvement Amendments (CLIA) certified laboratoryXx_NEWLINE_xXRECURRENT/ PROGRESSIVE DIPG (STRATUM 1): Patients must have had their last fraction of: \r\n* Craniospinal irradiation or radiation to >= 50% of pelvis > 3 months prior to enrollment\r\n* Focal irradiation to the primary site > 42 days prior to enrollment\r\n* Local palliative irradiation other than previously irradiated primary site (small port) >= 14 daysXx_NEWLINE_xXNON-PROGRESSED DIPG (STRATUM 2): Patients must have had their last fraction of focal irradiation to the primary site > 14 days prior to enrollment; patients must not have received local palliative irradiation or craniospinal irradiationXx_NEWLINE_xXWilling to remain on-site for approximately 24 hours after administration of AVB-620 or, if required, stay overnight after the surgical procedureXx_NEWLINE_xXAdenocarcinoma or carcinoma of unknown primary siteXx_NEWLINE_xXPatient is a staff member of the sponsor or clinical site and is involved in the conduct of the study or the relative of such a staff member. Patient Exclusion Criteria - Part 2:Xx_NEWLINE_xXPatient is a staff member of the sponsor or clinical site and is involved in the conduct of the study or the relative of such a staff memberXx_NEWLINE_xXDocumentation of HER2 overexpression or gene amplification in the invasive component of either the primary tumor or metastatic disease site defined as:Xx_NEWLINE_xXAll melanomas, except ocular/uveal melanoma, regardless of primary site of disease will be allowed; mucosal melanomas are eligible.Xx_NEWLINE_xXTumor tissue from the resected site of disease must be provided for biomarker analysesXx_NEWLINE_xXDiagnosis of recurrent or metastatic SCCHN on any site except lip, thyroid, salivary gland, or nasopharynxXx_NEWLINE_xXGeneralized dermatologic conditions (such as allergic reactions, infection, edema, or scarring) that will not allow for study drug administration at a site of normal skin or evaluation of localized adverse eventsXx_NEWLINE_xXSubjects who fail to comply with site requirements for cessation of medication that interfere or increase procedure risk.Xx_NEWLINE_xXDestruction of cortical bone at impending fracture site > 50%. -Actual Fracture-Specific Inclusion CriteriaXx_NEWLINE_xXPrimary tumor (osteogenic origin, etc.) at site.Xx_NEWLINE_xXActive or incompletely treated infections that could involve the device implant site.Xx_NEWLINE_xXDistant foci of infection that may spread to the implant site.Xx_NEWLINE_xXDestruction of cortical bone at impending fracture site < 50%.Xx_NEWLINE_xXPrior surgery and/or prior fracture of affected site.Xx_NEWLINE_xXAny articular component to impending fracture site. -Actual Fracture-Specific Exclusion CriteriaXx_NEWLINE_xXPatients whose intramedullary canal at site of fracture measures smaller than the diameter of the sheath provided.Xx_NEWLINE_xXDocumented IDH2 gene-mutated disease based on local site testingXx_NEWLINE_xXUse of topical corticosteroids at or near the intended administration site;Xx_NEWLINE_xXAccessibility to the site that optimizes the subject's ability to keep all study-related appointments.Xx_NEWLINE_xXGeographically accessible to site, i.e. the ability to come to the study site for each scheduled appointment and evaluation.Xx_NEWLINE_xXA target bleeding site can be identified.Xx_NEWLINE_xXTarget bleeding site is identified on the cut raw liver surface (resection area).Xx_NEWLINE_xXA target bleeding site cannot be identified.Xx_NEWLINE_xXAvailable tumor site amenable to core needle biopsy as determined by the treating investigator; any questions regarding suitability of site for biopsy will be adjudicated by the principal investigatorXx_NEWLINE_xXAt least one MIBG avid bone site or diffuse MIBG uptake.Xx_NEWLINE_xXAt least one soft tissue site that meets criteria for a TARGET lesion defined by:Xx_NEWLINE_xXIn addition to size, a site needs to meet one of the following criteria: MIBG avid. For patients with persistent disease only: If a patient has only 1 or 2 MIBG avid lesions OR a Curie Score of 1 - 2, then biopsy confirmation of neuroblastoma and/or ganglioneuroblastoma in at least one site present at time of enrollment (either bone marrow, bone and/or soft tissue) is required to be obtained at any time point prior to enrollment and at least two weeks subsequent to most recent prior therapy. If a patient has 3 or more MIBG avid lesions OR a Curie Score of ? 3 then no biopsy is required for eligibility.Xx_NEWLINE_xXParticipants with circumstances that will not permit completion of the study or required follow-up; for instance, if travel to and from treatment site is an issueXx_NEWLINE_xXDisease status\r\n* Tumors must have NOT been completely resected, or must be locoregionally recurrent if previously resected; tumor must be deemed potentially resectable by local surgeon\r\n* MM arising from the head/neck, genitourinary, or gastrointestinal tract\r\n* Disease meets any 1 of 4 characteristics:\r\n** Regional lymph node (LN) involvement; OR\r\n** Multifocal/satellite primary disease; OR\r\n** Single localized, primary disease meeting one of the following site-specific requirements:\r\n*** Head/neck – any primary lesion if sinonasal; pT4a or above for nasal or oral cavity\r\n*** Anorectal – any primary lesion\r\n*** Conjunctiva – any primary lesion T2 or T3 stage by American Joint Committee on Cancer (AJCC)\r\n*** Vaginal/cervical – any primary\r\n*** Vulvar (hair bearing surface, labia majora) – AJCC cutaneous stage IIB or higher\r\n*** Esophageal – any primary\r\n** Locoregionally recurrent following prior resection\r\n* No evidence of metastatic disease at the time of registrationXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXOncology physicians must work at a National Cancer Institute (NCI) Community Oncology Research Program (NCORP) practice site with no plans to leave that NCORP practice site or retire at the time of enrollment into the studyXx_NEWLINE_xXSite must verify that there is no known change in the step 1 eligibility since initial registrationXx_NEWLINE_xXPatients with a radiographic or pathologic fracture to the treatment siteXx_NEWLINE_xXPORT SITE CLOSURE TECHNIQUE:Xx_NEWLINE_xXIndividuals with significant psychiatric disturbance that require a higher level of care; this determination will be at the discretion of the healthcare provider, site principal investigator (PI); as appropriate and determined by the site PI, the study PI may be consulted to discuss determination of participant eligibilityXx_NEWLINE_xXIndividuals with substance abuse/dependence problems that require a higher level of care; this determination will be at the discretion of the healthcare provider or site PI; as appropriate and determined by the site PI, the study PI may be consulted to discuss determination of participant eligibilityXx_NEWLINE_xXPatients with persistent distinguishable pain associated with 1 site to be treated (if patient has pain from additional sites, the pain from the additional sites must be evaluated as being less intense by at least 2 points on the NRS compared to the site to be treated).Xx_NEWLINE_xXTargeted tumor is at an impending fracture site (>7 on fracture risk score, see Section 7.4). ORXx_NEWLINE_xXPatients with surgical stabilization of tumor site with metallic hardwareXx_NEWLINE_xXThe targeted tumor is less than 2 points more painful compared to other painful lesions on the site specific NRS.Xx_NEWLINE_xXIndividuals that are unwilling or unable to attend study visits or are planning to move out of a study site coverage area during the subject’s anticipated participation in the studyXx_NEWLINE_xXPrior surgery in the same site in the breastXx_NEWLINE_xXTechnical contraindications to epidural placement: previous thoracic spinal surgery or local skin or soft tissue infection at proposed site for epidural insertionXx_NEWLINE_xXLymphedema Group: Reliable transportation to the study siteXx_NEWLINE_xXNo Lymphedema Group: Reliable transportation to the study siteXx_NEWLINE_xXAs per self-report, a current caregiver to a patient with any site or stage of cancerXx_NEWLINE_xXHistory of abdominal surgery precluding free flap donor siteXx_NEWLINE_xXUpper extremity deformity contralateral to the site of disease that could interfere with accurate point location or alter the energy pathway as defined by traditional acupuncture theoryXx_NEWLINE_xXLocal skin infections at or near the acustimulation siteXx_NEWLINE_xXHistory of cerebral vascular accident (CVA) or other central nervous system disorder resulting in residual weakness or paresis of extremity contralateral to the site of diseaseXx_NEWLINE_xXSurgery that would not allow access to at least one P6 siteXx_NEWLINE_xXAll patients must have no more than 3 contiguous vertebral body levels treated at a single site, and no more than 3 discontiguous vertebral body levels treatedXx_NEWLINE_xXAll patients must have a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gray (Gy)Xx_NEWLINE_xXAll patients must have a vertebral body site to be treated located from T1 to L5Xx_NEWLINE_xXPatients who have had prior radiotherapy at the spine site and level to be treatedXx_NEWLINE_xXPathologically confirmed gastric, gastroesophageal junction (GEJ) or esophageal, adenocarcinoma at either Memorial Sloan-Kettering Cancer Center (MSKCC) or a participating site (biopsy may be performed at other institutions but slides must be confirmed at MSKCC or a participating site, as is routine care at our institution)Xx_NEWLINE_xXActive infection or ulcer at the lumbar injection siteXx_NEWLINE_xXLives within a two-hour commuting distance from the recruitment siteXx_NEWLINE_xXCraniotomy or intracranial biopsy site must be adequately healed, free of drainage or cellulitis, and the underlying cranioplasty must appear intact at the time of study entryXx_NEWLINE_xXParticipant must not have already worked with the staff writer at Dartmouth Hitchcock prior to enrollment in this studyXx_NEWLINE_xXResidence > 70 miles from research siteXx_NEWLINE_xXInternational Classification of Disease, 9th revision (ICD 9) cancer diagnosis seen at each site in the past two yearsXx_NEWLINE_xXActive or known prior infection at the pseudarthrosis siteXx_NEWLINE_xXParticipant plans to relocate away from the study site during study participationXx_NEWLINE_xXWilling to drive to the study siteXx_NEWLINE_xXPresence of extensive skeletal metastases defined as more than five (5) sites of bony disease, or any symptomatic site of disease in the spine, hip, or femur; Note that, patients with more than five bony sites may be deemed eligible at the discretion of the attending oncologistXx_NEWLINE_xXPatients must be willing and able to travel to the pulmonary rehabilitation site at the Morehouse Medical PlazaXx_NEWLINE_xXPatient has metal implants near the surgical site that preclude treatment with the microwave systemXx_NEWLINE_xXPatient or caregivers who are unwilling or incapable of maintaining a detailed log of number of injections, the date, time and site of administrationXx_NEWLINE_xXClinical evidence of skin infection at the potential site of IPC placementXx_NEWLINE_xXLocal infection at or near the acupuncture site; (although acupuncture is a minimally invasive procedure, patients will be excluded if there is an indication of infection)Xx_NEWLINE_xXResidual grade > 1 skin toxicity, cellulitis, or incompletely healed wound(s) at intended site of study drug application at the time of the start of radiation therapy (RT)Xx_NEWLINE_xXTechnical contraindications to epidural placement: previous thoracic spinal surgery or local skin or soft tissue infection at proposed site for epidural insertionXx_NEWLINE_xXAble to travel to the retreat siteXx_NEWLINE_xXLocal infection at or near the acupuncture site (although acupuncture is a minimally invasive procedure, patients will be excluded if there is an indication of infection)Xx_NEWLINE_xXReside in California or receive care at a Sanford Health siteXx_NEWLINE_xXParticipant plans to relocate away from the study site to a location that does not have an Anal Cancer/HSIL Outcomes Research (ANCHOR) study site during study participationXx_NEWLINE_xXMetal implants on same limb as intended administration siteXx_NEWLINE_xXTattoos, scars, active lesions, or rashes =< 2 cm of the intended site of study treatmentXx_NEWLINE_xXSITE ELIGIBILITY (AS PER SC SELF-REPORT)Xx_NEWLINE_xXMust be designated as an American College of Radiology (ACR) designated lung cancer screening siteXx_NEWLINE_xXSITE COORDINATOR (SC) ELIGIBILITY (AS PER SELF-REPORT)Xx_NEWLINE_xXEmployed as a full-time Site Coordinator at participating lung cancer screening siteXx_NEWLINE_xXHave an acute illness, as determined by the site principal investigator within 72 hours prior to study vaccination; an acute illness which is nearly resolved with only minor residual symptoms remaining is allowable if, in the opinion of the site principal investigator, the residual symptoms will not interfere with the ability to assess safety parameters as required by the protocol and was not due to an influenza infectionXx_NEWLINE_xXPrimary site may include oral cavity, pharynx, or larynx; oropharynx primaries must be human papilloma virus (HPV) (-) as defined by routine p16 immunohistochemistry (IHC) at the local siteXx_NEWLINE_xXIndividuals with a history of any skin cancer, melanocytic lesions, actinic keratoses or actinic damage in the test area are ineligible; history of such conditions at a body site other than the test area is not exclusionary if in the opinion of the study physician it will not pose a risk to the subjectXx_NEWLINE_xXUp to three small (? 3 cm each) lung oligometastases will be allowed and/or one oligometastasis at any other site in the bodyXx_NEWLINE_xXBiopsies performed at outside institutions should have Gleason score confirmed at the study site by a genitourinary (GU) pathologist to ensure eligibilityXx_NEWLINE_xXIs or has an immediate family member (e.g., spouse, parent/legal guardian, sibling or child) who is investigational site or sponsor staff directly involved with this trial.Xx_NEWLINE_xXPatients with hematomas or biopsy site changes that limit response assessment of the primary tumor by diagnostic imagingXx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)Xx_NEWLINE_xXWillingness to return to the enrolling site for any surgical procedures including pre-operative and post-operative careXx_NEWLINE_xXInvolvement in the planning and conduct of the study (applies to both Astra Zeneca staff and staff at the study site)Xx_NEWLINE_xXIs or has an immediate family member who is investigational site or sponsor staff directly involved with this studyXx_NEWLINE_xXSigns and symptoms of localized catheter-related infection (tenderness and/or pain, erythema, swelling, purulent exudates within 2 cm of entry site)Xx_NEWLINE_xXAmbulatory, able to come to either food distribution site to pick up food and participate in clinical examinations and laboratory testsXx_NEWLINE_xXPatients without breast biopsy marker documented by imaging at tumor bed site prior to initiation of neoadjuvant therapyXx_NEWLINE_xXPrior radiation or ablative therapy to intended site of biopsy, if within the prostate bedXx_NEWLINE_xXRadiation to the recurrent or metastatic site is clinically indicated and would be considered standard care for palliation or for locoregional controlXx_NEWLINE_xXTumor site amenable to MRI guided biopsy as determined by the radiologistXx_NEWLINE_xXCancer located on a site that may not be convenient or accessible for imaging with the current version of the RCM device (gingivobuccal region, back of the oral cavity, back of the tongue, floor of the mouth, deep under the tongue, etc.)Xx_NEWLINE_xXKnown or suspected renal impairment; requirements for GFR prior to MRI as determined by local site standard practiceXx_NEWLINE_xXPatients with extensive prior surgery at the primary site or nodal basin expected to affect the lymphatic drainageXx_NEWLINE_xXPatients who have had surgery at the site of the suspected lesion within 1 monthXx_NEWLINE_xXPatients must have MIBG evaluable disease which is defined as evidence of uptake into tumor at >= one site within 4 weeks prior to entry on study and subsequent to any intervening therapyXx_NEWLINE_xXPatients must have measurable residual disease at the primary site, after surgery or at relapse as estimated by imagingXx_NEWLINE_xXPre-operative radiation to primary tumor siteXx_NEWLINE_xXtesting on site at the institution (urine or serum ßHCG) within 24 hours prior to the start of investigational product administrationXx_NEWLINE_xXAt least one site of disease 1.5 cm or greater is needed to meet the spatial resolution limits of PET imagingXx_NEWLINE_xXPatients who have had surgery at the site of the suspected lesion within 1 monthXx_NEWLINE_xXAt least 1 site of metastasis >= 20 mm in mean diameter must be identifiedXx_NEWLINE_xXMohs surgery located on a site that may not be convenient to confocal imagingXx_NEWLINE_xXWillingness to abstain from the application of lotions and/or creams to the area with HSV lesions. Wet/dry saline dressings or bandages at lesion site are allowed.Xx_NEWLINE_xXNot able to communicate meaningfully with the Investigator and site staff.Xx_NEWLINE_xXInvolvement in the planning and/or conduct of the study (applies to both AstraZeneca, Contract Research Organization [CRO] staff, and/or staff at the CPU)Xx_NEWLINE_xXFor cohort 1 only: evidence of disease progression =< 14 months prior to registration according to RECIST 1.1, as confirmed by the site study principal investigator (PI)Xx_NEWLINE_xXFor cohort 2 only: progressive disease (PD) on lenvatinib per RECIST 1.1 =< 30 days prior to registration, as confirmed by the site study PIXx_NEWLINE_xXDYNAMIC COHORT: Clinical plan for biopsy or surgical procedure of at least one site of known or suspected cancerXx_NEWLINE_xXSubjects must have at least 1 tumor site that can be biopsied at acceptable clinical risk and must consent to pre- and post-treatment biopsiesXx_NEWLINE_xXthe safety or well-being of the participant or study staffXx_NEWLINE_xXMinimum provider participation requirements met; this includes participation in the study intervention of a minimum of the following: Site Coordinator and Site Clinician Investigator/study championXx_NEWLINE_xXSite Coordinator identification and contact with as many as possible of the site’s relevant healthcare providers and staff regarding participation in the study intervention; relevant providers may include physicians, nurse practitioners, physician assistants, patient navigators, nurses and other staff who interact directly with breast cancer patientsXx_NEWLINE_xXOn-site genetics professionals as defined by the Commission on CancerXx_NEWLINE_xXSTUDY SITE ELIGIBILITY:Xx_NEWLINE_xXHas a study site-specific nurse available to act as a PN or has a (study site-specific or shared) nurse available to act as a “clinical consultant” to a study site-specific, non-nurse navigator\r\n* Study sites randomized to the Intervention Arm are not eligible to register subjects (nor administer the protocol intervention), until the site’s identified PN(s) has/have completed the protocol-specific navigation trainingXx_NEWLINE_xXEvaluated/treated for NSCLC at an eligible study siteXx_NEWLINE_xXPatient is being treated at a Duke Cancer Network (DCN) affiliate siteXx_NEWLINE_xXGARAGE/SITE EXCLUSION:Xx_NEWLINE_xXHas an exocrine GI cancer with MSKCC pathology confirmation at the primary or metastatic anatomic siteXx_NEWLINE_xXUndergoing routine oncology care and surveillance at the chosen site (defined as receiving follow-up care with FCCC or FCCCP site health care providers and have an active medical chart)Xx_NEWLINE_xXHealth care providers at the participating site must be willing and able to participate in the educational initiativeXx_NEWLINE_xXPatients who do not undergo routine oncologic care at the chosen Partners site or Fox Chase Cancer CenterXx_NEWLINE_xXAny Grady patient who has been consented to receive chemotherapy on trial or as standard of care; there is no restriction by disease site or stage of diseaseXx_NEWLINE_xXAdenocarcinoma or carcinoma of unknown primary site (UKPS).Xx_NEWLINE_xXExpected to require other cancer therapy while on study with the exception of local palliative radiation treatment to the site of bone and other metastasis.Xx_NEWLINE_xX